Summary
The provided label text supports antibacterial-only use and emphasizes drug resistance and CDAD risk, but most claims in the list concern topical acne use, application instructions, and specific irritation/avoidance locations, which are not supported by the supplied prescribing information for SAGENT® clindamycin injection (parenteral IM/IV).
Category Scores
Accurate Statements
Clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria, and prescribing without such bacterial indication is unlikely to provide benefit and increases risk of drug-resistant bacteria.
Supported by SECTION 1 INDICATIONS AND USAGE and SECTION 5 PRECAUTIONS excerpts: restriction to proven/strongly suspected susceptible bacterial infections; and that prescribing without such indication increases drug resistance and is unlikely to provide benefit.
Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents including clindamycin, and may range from mild diarrhea to fatal colitis.
Supported by SECTION 5 WARNINGS CDAD boxed warning language.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
Supported by SECTION 5 WARNINGS excerpt regarding discontinuation of non–C. difficile-directed antibiotics if CDAD suspected/confirmed.
Unsupported Statements
Fougè ra clindamycin phosphate gel is a topical antibiotic.
Not supported by the provided label excerpts, which relate to SAGENT® clindamycin injection (sterile solution for IM/IV).
Fougè ra clindamycin phosphate gel is used to treat acne.
Not supported by the provided label excerpts.
Fougè ra clindamycin phosphate gel treats acne by reducing bacteria in the skin.
Not supported by the provided label excerpts.
Fougè ra clindamycin phosphate gel treats acne by reducing inflammation in the skin.
Not supported by the provided label excerpts.
Clindamycin phosphate for topical use is generally a prescription medicine in the U.S.
Not supported by the provided label excerpts.
Clindamycin phosphate gel is marketed as a gel formulation (clindamycin phosphate).
Not supported by the provided label excerpts (parenteral injection label excerpts provided).
The exact concentration of clindamycin phosphate gel depends on the specific product listing by the manufacturer/label.
Not supported by the provided label excerpts.
Typical acne regimens involve applying a thin layer of clindamycin phosphate gel to the affected skin area once or twice daily.
Not supported by the provided label excerpts.
Clindamycin phosphate gel should be applied consistently.
Not supported by the provided label excerpts.
Clindamycin phosphate gel should be used only on affected areas.
Not supported by the provided label excerpts.
Clindamycin phosphate gel should be avoided on eyes.
Not supported by the provided label excerpts.
Clindamycin phosphate gel should be avoided on lips.
Not supported by the provided label excerpts.
Clindamycin phosphate gel should be avoided on the inner nose.
Not supported by the provided label excerpts.
Topical clindamycin can cause local skin irritation such as dryness.
Not supported by the provided label excerpts.
Topical clindamycin can cause local skin irritation such as redness.
Not supported by the provided label excerpts.
Topical clindamycin can cause local skin irritation such as itching.
Not supported by the provided label excerpts.
Topical clindamycin can cause local skin irritation such as burning.
Not supported by the provided label excerpts.
Antibiotic-associated diarrhea from antibiotic products can be severe.
Label excerpt supports CDAD severity range (mild to fatal colitis), but the claim is generalized and not tied specifically to the label-provided CDAD description.
Severe diarrhea associated with antibiotic products requires medical attention.
Not supported by the provided label excerpts.
Acne improvements with topical antibiotics usually take several weeks.
Not supported by the provided label excerpts.
Many acne regimens using topical antibiotics are evaluated for response after about 6–12 weeks.
Not supported by the provided label excerpts.
Patients are usually advised to avoid using clindamycin phosphate gel on broken skin unless a clinician recommends it.
Not supported by the provided label excerpts.
Patients are usually advised to use caution with other topical products that can irritate skin, such as strong exfoliants or retinoids, if irritation develops.
Not supported by the provided label excerpts.
Patients are advised to seek care if significant or persistent diarrhea occurs.
Not supported by the provided label excerpts.
Fougè ra clindamycin phosphate gel is a branded version of topical clindamycin.
Not supported by the provided label excerpts.
Other brands or generics of topical clindamycin may differ in concentration.
Not supported by the provided label excerpts.
Other brands or generics of topical clindamycin may differ in excipients.
Not supported by the provided label excerpts.
Other brands or generics of topical clindamycin may differ in dosing instructions based on their specific label.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Use limitation to proven/strongly suspected susceptible bacterial infections and avoidance of nonbacterial/viral infections (the label explicitly includes this counseling/rationale for clindamycin).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Most claims are about a topical acne gel and specific application precautions not supported by the supplied label excerpts (which pertain to clindamycin injection). Misalignment could lead to inappropriate use/application relative to on-label instructions. However, some label-supported statements about antibacterial-only use and CDAD severity exist in the provided claims set.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Needs Review
Primary Issue
Claims largely reference a topical acne gel and detailed use/application guidance, but the supplied FDA label excerpts are for clindamycin injection (IM/IV) and do not support topical acne indication, dosing/application frequency, or site-specific avoidance/irritation expectations for a gel.
Suggested Improvement
Restrict statements to what the provided label excerpts support: antibacterial-only use for proven/strongly suspected susceptible bacterial infections, avoidance of nonbacterial/viral infections, drug-resistance rationale, and CDAD severity/discontinuation guidance. Remove or clearly label unsupported topical acne/dosing/application and irritation-location claims absent matching label text.